Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 10, 2008
JNCI Journal of the National Cancer Institute 2008 100(12):831-833; doi:10.1093/jnci/djn177
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/12/831    most recent
djn177v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jordan, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, V. C.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

EDITORIALS

The Rise of Raloxifene and the Fall of Invasive Breast Cancer

V. Craig Jordan

Affiliation of author: Fox Chase Cancer Center, Philadelphia, PA

Correspondence to: V. Craig Jordan, OBE, PhD, DSc, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111-2497 (e-mail: v.craig.jordan@fccc.edu).

The first 10% of the full text of this article appears below.

Bernard Fisher has recently stated, "A clinical trial is just a mechanism by which to evaluate what you have done in the laboratory" (Oncology News International, March 2008). In this issue of the Journal, Grady et al. (1) have analyzed the incidence of invasive breast cancer in a clinical trial of women treated with raloxifene with the intention of reducing their risk of dying from coronary heart disease. To the casual observer, an analysis of this nature would seem to be unusual, if not a bit bizarre, but the fact is that raloxifene is a selective estrogen receptor modulator (SERM) that has estrogen-like activity to reduce low-density lipid (LDL) cholesterol (2) and to reduce the risk of fractures in osteoporosis (3), and antiestrogenic properties to block the growth of breast cancers . . . [Full Text of this Article]

Funding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk
Deborah Grady, Jane A. Cauley, Mary Jane Geiger, Marcel Kornitzer, Lori Mosca, Peter Collins, Nanette K. Wenger, Jingli Song, John Mershon, and Elizabeth Barrett-Connor For the Raloxifene Use for The Heart Trial Investigators
J Natl Cancer Inst 2008 100: 854-861. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2008 100: 829. [Extract] [Full Text] [PDF]

Raloxifene Reduces Risk of Invasive Estrogen-Receptor Positive Breast Cancer
J Natl Cancer Inst 2008 100: 829. [Extract] [Full Text] [PDF]